The US Food and Drug Administration (FDA) has appointed Genzyme’s Dr Richard Moscicki to the newly created position of deputy centre director for science operations at its Center for Drug Evaluation and Research (CDER).
Dr Moscicki, who currently serves as senior VP, head of clinical development at Sanofi’s Genzyme division, will help lead the CDER in its role to regulate over-the-counter and prescription-only drugs available in the US.
The FDA will benefit from his strong industry background in research, which includes time spent as medical director and chief medical officer at Genzyme.
He also gained regulatory and pharmacovigilance experience at the US-based biotech, serving as its senior VP of biomedical and regulatory affairs from 1996 to 2011.
In his role at the FDA, Dr Moscicki will work with Dr Bob Temple, deputy director for clinical science, and Dr Doug Throckmorton, deputy director for regulatory programmes.